Impact of new non-cytotoxics in the treatment of ovarian cancer

This publication has 17 references indexed in Scilit:

• Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
  New England Journal of Medicine, 2001
• Serum Vascular Endothelial Growth Factor in Epithelial Ovarian Neoplasms: Correlation with Patient Survival
  Gynecologic Oncology, 1999
• Vascular Endothelial Growth Factor Expression as a Prognostic Index in Serous Ovarian Cystoadenocarcinomas: Relationship with MIB1 Immunostaining
  Gynecologic Oncology, 1999
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
  Oncogene, 1999
• Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
  JNCI Journal of the National Cancer Institute, 1998
• Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor
  European Journal of Obstetrics & Gynecology and Reproductive Biology, 1997
• c‐crbB2 gene amplification and protein expression in ovarian epithelial tumors: Evaluation of their respective prognostic significance by multivariate analysis
  International Journal of Cancer, 1995
• Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
  The Lancet, 1992
• What Is the Evidence That Tumors Are Angiogenesis Dependent?
  JNCI Journal of the National Cancer Institute, 1990
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987